Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641299 · ClinicalTrials.gov registry record · Phase 2
A Study of AZD8233 in Participants With Dyslipidemia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT04641299 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 119 participants.
The verdict
NCT04641299, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD monitoring in the further clinical development program.
Interventions
- DRUG Placebo
- DRUG AZD8233
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-07-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04641299
The ClinicalTrials.gov registry entry for NCT04641299 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04641299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04641299 about?
NCT04641299 is a clinical study titled "A Study of AZD8233 in Participants With Dyslipidemia". AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice ...
What is the current status of trial NCT04641299?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2020-10-28. Estimated completion is 2021-07-20.
What interventions are being tested in trial NCT04641299?
The interventions under investigation include: Placebo (DRUG), AZD8233 (DRUG).
Who is sponsoring clinical trial NCT04641299?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.